Autologous haematopoietic stem cell transplantation (HSCT) has proved efficacious in treating patients with systemic sclerosis, but different regimens have different associated toxicities and different effects on lung function. Through comparison of different clinical trials, we can learn how to improve the safety of HSCT.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Mesenchymal stem cell as a novel approach to systemic sclerosis; current status and future perspectives
Cell Regeneration Open Access 01 December 2020
-
CD34-selected versus unmanipulated autologous haematopoietic stem cell transplantation in the treatment of severe systemic sclerosis: a post hoc analysis of a phase I/II clinical trial conducted in Japan
Arthritis Research & Therapy Open Access 22 January 2019
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Sullivan, K. M. et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. N. Engl. J. Med. 378, 35–47 (2018).
van Laar, J. M. et al. Autologous hematopoietic stem cell transplantation versus intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 311, 2490–2498 (2014).
Burt, R. K. et al. Aurtologous non-myeloablative haematopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomized phase II study. Lancet 378, 498–506 (2011).
Burt, R. K. et al. Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis. Lancet 381, 1116–1124 (2013).
Burt, R. K., Oliveira, M. C. & Shah, S. J. Cardiac assessment before stem cell transplantation for systemic sclerosis. JAMA 312, 1803 (2014).
Burt, R. K. et al. Hematopoietic stem cell transplantation for systemic sclerosis: if you are confused, remember: “it is a matter of the heart”. J. Rheumatol. 39, 206–209 (2012).
Farge, D. et al. Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners. Bone Marrow Transplant. 52, 1495–1503 (2017).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02516124 (2017).
Snowden, J. A. et al. Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. Blood Adv. 1, 2742–2755 (2017).
Farge, D. et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica 95, 284–292 (2010).
Acknowledgements
The authors would like to dedicate this manuscript to the memory of Walter Barr, Professor of Rheumatology at Northwestern University, Chicago, IL, USA (1949–2008). The authors would also like to thank John A. Snowden at the Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK for review of the manuscript and for constructive comments.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary information S1 (table)
Comparison of ASSIST, ASTIS and SCOT trials. (PDF 138 kb)
PowerPoint slides
Rights and permissions
About this article
Cite this article
Burt, R., Farge, D. Autologous HSCT is efficacious, but can we make it safer?. Nat Rev Rheumatol 14, 189–191 (2018). https://doi.org/10.1038/nrrheum.2018.34
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2018.34
This article is cited by
-
Umbilical cord mesenchymal stem cells transplantation in patients with systemic sclerosis: a 5-year follow-up study
Clinical Rheumatology (2024)
-
Cardiac safe hematopoietic stem cell transplantation for systemic sclerosis with poor cardiac function: a pilot safety study that decreases neutropenic interval to 5 days
Bone Marrow Transplantation (2021)
-
Long term outcomes of the French ASTIS systemic sclerosis cohort using the global rank composite score
Bone Marrow Transplantation (2021)
-
Mesenchymal stem cell as a novel approach to systemic sclerosis; current status and future perspectives
Cell Regeneration (2020)
-
Safety and efficacy of HSCT for systemic sclerosis across clinical trials
Nature Reviews Rheumatology (2020)